Anavex Life Sciences Corp. (NASDAQ: AVXL)

This lawsuit is for anyone who acquired securities in Anavex Life Sciences Corp. (NASDAQ: AVXL) from February 1, 2022 through January 1, 2024.

The lawsuit alleges that the Company and certain of its executives violated federal law. Specifically, the lawsuit alleges that, throughout the time period mentioned above, the Company misled investors regarding its financial condition. More specifically, the lawsuit alleges that the Company misled investors by continually changing the Company’s primary endpoint for its Phase 2/3 EXCELLENCE Clinical Study in Pediatric Rett Syndrome without timely informing investors.

On January 2, 2024, Anavex announced results from a Phase 2/3 EXCELLENCE Clinical Study in Pediatric Rett Syndrome, reporting that the “co-primary endpoint . . . was not met.” The Company blamed deficiencies in the study on “large placebo effect which may have masked the compound’s therapeutic effect,” despite no evidence to support that claim. On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume.

The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in Anavex Life Sciences Corp. (NASDAQ: AVXL) from February 1, 2022 through January 1, 2024 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.